| Botulinum toxin type A treatment for Parkinsonian patients with moderate to severe sialorrhea. | |
| | |
MedLine Citation:
|
PMID: 16995596 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To investigate the effect of botulinum toxin type A (BTX-A; Botox) in reducing saliva in patients with Parkinsonism. METHODS: Fifteen patients with clinical diagnosis of idiopathic Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy were enrolled in this open clinical trial. A total of 40-unit dose of Botox was injected into the bilateral parotid and submandibular glands. Objective measuring of saliva production with dental rods, subjective Drooling Score, personal impression of clinical improvement, and the duration of response were used for the global assessment of sialorrhea after BTX-A treatment. RESULTS: All patients showed objective reduction in saliva production following BTX-A treatment and the mean production was reduced at a significant level. The severity of sialorrhea assessed by Drooling Score was 5.87 +/- 0.92 (range: 5-8) and 3.60 +/- 1.18 (range: 2-6) respectively (p<0.001) before and after BTX-A injection. The mean duration of BTX-A response extended for 16.3 +/- 5.7 weeks (range: 5-24). No severe adverse effect nor worsening of existing dysphagia was observed in all Parkinsonian patients. CONCLUSIONS: Parkinsonian drooling may undermine patient's health and daily activity. BTX-A local injection is a safe and effective measure in counteracting sialorrhea, even in patients associated with moderate dysphagia. |
| | |
Authors:
|
Cheng-San Su; Min-Yu Lan; Jia-Shou Liu; Chiung-Chih Chang; Shung-Lon Lai; Hsiu-Shan Wu; Shun-Sheng Chen; Yung-Yee Chang |
Related Documents
:
|
3046226 - A controlled release form of madopar in parkinsonian patients with advanced disease and... 3209626 - Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide ... 19691126 - Onset and spread of dyskinesias and motor symptoms in parkinson's disease. 3428306 - A sustained-release formulation of l-dopa (madopar hbs) in the treatment of nocturnal a... 23164686 - Video capsule endoscopy in patients with nonresponsive celiac disease. 6092406 - Decreased nuclear uptake of [125i]triiodo-l-thyronine in fibroblasts from patients with... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Acta neurologica Taiwanica Volume: 15 ISSN: 1028-768X ISO Abbreviation: Acta Neurol Taiwan Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-09-25 Completed Date: 2006-10-26 Revised Date: 2008-05-28 |
Medline Journal Info:
|
Nlm Unique ID: 9815355 Medline TA: Acta Neurol Taiwan Country: China (Republic : 1949- ) |
Other Details:
|
Languages: eng Pagination: 170-6 Citation Subset: IM |
Affiliation:
|
Department of Neurology, Chang-Gung Memorial Hospital, Kaohsiung, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Botulinum Toxin Type A / adverse effects, therapeutic use* Female Humans Injections Male Parkinsonian Disorders / complications* Sialorrhea / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Botulinum Toxin Type A |
| Comments/Corrections | |
Comment In:
|
Acta Neurol Taiwan. 2006 Sep;15(3):151-3
[PMID:
16995593
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic characteristics of dementia in Taiwan.
Next Document: Temporal patterns of body temperatures in the acute stage of stroke.